Clinical reference Biomarker Directory
Back to directory

Triosephosphate Isomerase

Emerging

TPI deficiency is the most severe glycolytic enzyme deficiency, combining hemolytic anemia with progressive neurological decline.

Also known as TPI TPI1
In plain language

This is the most serious of the related red-cell enzyme deficiencies discussed in this group, since it causes not just anemia but also progressive nerve and brain problems that don't respond to the usual anemia treatments.

Biomarker & context

Triosephosphate isomerase (TPI) is a glycolytic enzyme whose deficiency causes one of the most severe conditions among the red cell enzymopathies discussed in this biomarker set.

What it indicates

TPI deficiency is notably the most severe of the glycolytic enzyme deficiencies, often causing progressive neurological deterioration in addition to hemolytic anemia, distinguishing it from the milder, purely hematologic presentations of GPI, hexokinase, and pyruvate kinase deficiency.

Diagnosis & clinical testing

Diagnosed via red blood cell enzyme activity assay combined with genetic testing (TPI1 gene), given the severity and prognostic importance of confirming this specific diagnosis among the broader group of glycolytic enzymopathies.

Guiding treatment

Management is largely supportive and often limited by the progressive neurological component, which doesn't respond to standard anemia management (transfusions) the way the hematologic component does, making this a particularly difficult condition among the enzyme deficiencies discussed in this set.

Clinical significance

The neurological component doesn't respond to standard anemia treatments, making this a particularly difficult condition to manage.

References
  1. General metabolic disease reference literature on triosephosphate isomerase deficiency and its neurological complications.